CHD - Church & Dwight Q4: Reiterate Buy Rating As Growth Outlook Remains Bright
2024-02-06 04:22:43 ET
Summary
- I continue to think CHD is a buy due to strong innovation, increased marketing spend, and contributions from Hero and TheraBreath.
- Management guided for 4-5% net sales growth in FY24.
- The company's focus on core brands, upcoming innovations, and acquisitions is expected to drive organic sales growth and support the current valuation.